Compare BridgeBio Pharma Inc (BBIO) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Western Union Co — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Western Union Co trades at $7.05 (market cap $2.19B). The key difference: BridgeBio Pharma Inc is far larger — about 7.6× Western Union Co's market cap, and Western Union Co pays a 13.37% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | WU | |
|---|---|---|
Market Cap | $16.61B | $2.19B |
Sector | Health | Technology |
52-Week High | $90.17 | $10.28 |
52-Week Low | $47.29 | $6.36 |
Enterprise Value | $18.16B | $2.10B |
Dividend Yield | — | 13.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Western Union (WU) trades at $7.08, down 1.12% today, with a bearish technical signal and recent earnings misses in Q1 and Q2 2026. Valuation ratios appear attractive with a P/E of 5.71 and P/S of 0.56, but revenue has declined from $4.5B in 2022 to $4.05B in 2025. The company maintains a strong dividend yield, paying $0.24 quarterly, and recently launched Stablecard with Rain to expand digital services.
The outlook is cautious due to earnings volatility and competitive pressures in money transfers. Opportunities include cost management and digital growth, but risks from declining retail performance and high debt levels persist. Analyst consensus is mixed with a $7.14 price target, reflecting uncertainty over turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
